Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | STARD3 | Q14849 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329094 | 0.93 | CCR2 (0.44) | CCR2DRD4MEN1KMT2ABCHE | |
| SCHEMBL13249774 | 0.89 | PARP1 (0.45) | DRD4MEN1KMT2ADRD2KDM4E | |
| SCHEMBL13249775 | 0.86 | CCR2 (0.45) | CCR2GNRHRKDM4EALDH1A1 | |
| SCHEMBL13249777 | 0.85 | CLPP (0.46) | CCR2DRD4GNRHRDRD2KDM4E | |
| SCHEMBL13249817 | 0.84 | CLPP (0.48) | DRD4ACHEDRD2KDM4EALDH1A1 | |
| SCHEMBL13249773 | 0.84 | CLPP (0.49) | DRD4BCHEACHEBACE1GNRHR | |
| SCHEMBL13249826 | 0.84 | MAPT (0.41) | CCR2KMT2AACHEGNRHRKDM4E | |
| SCHEMBL13249835 | 0.84 | CLPP (0.46) | DRD4MEN1KMT2ADRD2HTR2A | |
| SCHEMBL13249807 | 0.83 | MGLL (0.40) | SIGMAR1ALDH1A1 | |
| SCHEMBL13249825 | 0.82 | ALDH1A1 (0.49) | MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | CCR2 134/4885STARD3 2839/4885DRD4 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.